Abstract
ZAP-70 and CD38 expression can identify B-cell chronic lymphocytic leukemia with an inferior clinical outcome. Many groups have investigated the meaning of the expression of these two proteins and the correlation with the bad prognosis in B-CLL. But nobody has investigated the relation between the multidrug resistance mediated by Pgp overexpression (MDR1) and ZAP-70/CD38 coexpression. Forty-one untreated and stage A patients, either ZAP-70(+)CD38(+) or ZAP-70(-)CD38(-), were tested to determine the MDR1 status. MDR1 was observed in 41% of CLL ZAP-70(+)CD38(+) and in 37% of CLL ZAP-70(-)CD38(-). The difference was not significant (p = 0.745). Patients with ZAP-70 and CD38 positive CLL can not be candidates for MDR1 antagonists.
MeSH terms
-
ADP-ribosyl Cyclase 1 / metabolism*
-
ATP Binding Cassette Transporter, Subfamily B
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
-
Aged
-
Aged, 80 and over
-
Drug Resistance, Multiple*
-
Drug Resistance, Neoplasm
-
Female
-
Gene Expression Regulation, Leukemic*
-
Humans
-
Immunoblotting
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
-
Male
-
Membrane Glycoproteins / metabolism*
-
Middle Aged
-
Prognosis
-
Up-Regulation
-
ZAP-70 Protein-Tyrosine Kinase / metabolism*
Substances
-
ABCB1 protein, human
-
ATP Binding Cassette Transporter, Subfamily B
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Membrane Glycoproteins
-
ZAP-70 Protein-Tyrosine Kinase
-
ZAP70 protein, human
-
CD38 protein, human
-
ADP-ribosyl Cyclase 1